Multiple Myeloma Bone Marrow Mononuclear Cells

Multiple Myeloma Bone Marrow Mononuclear Cells for Plasma Cell Disorder Research

Our Multiple Myeloma Bone Marrow Mononuclear Cells is a hematopoietic tissue sample isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples are sourced from IRB-consented donors clinically diagnosed with multiple myeloma, a malignancy of clonal plasma cells that reside and expand within the bone marrow.

Multiple Myeloma Biology and Why Bone Marrow

• Multiple myeloma diagnosis requires demonstration of clonal plasma cell infiltration of the bone marrow at 10% or greater (or a biopsy-proven plasmacytoma), making marrow aspirate the required diagnostic specimen.
• Fluorescence in situ hybridization (FISH) cytogenetics performed on marrow-derived plasma cells – detecting abnormalities such as t(4;14), t(14;16), and del(17p) – is the standard approach to risk stratification.
• The marrow microenvironment, including bone marrow stromal cells, osteoclasts, and immune cells, actively supports myeloma cell survival and drives the characteristic bone disease, making marrow material essential for microenvironment-focused research.
• Minimal residual disease assessment by next-generation flow cytometry or sequencing on marrow aspirate is increasingly used to guide treatment duration and predict outcomes.
• Novel immunotherapies, including BCMA-targeted CAR-T and bispecific antibodies, rely on marrow-derived plasma cells for target-expression and functional studies.

Donor Stratification Available

• Cytogenetic risk group, including t(4;14), t(14;16), and del(17p) status where documented
• Disease stage (R-ISS) and plasma cell percentage at collection
• Treatment history, including immunotherapy or stem cell transplant
• Light chain type and other biomarker status where documented
• Age band and sex assigned at birth
• Matched healthy bone marrow controls available

Product Features

• Isolated from clinically confirmed multiple myeloma donor bone marrow aspirate
• Density-gradient purified and cryopreserved
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom cell quantities available

De-identified Donor Data

• Multiple myeloma diagnosis confirmation and cytogenetic risk group where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Treatment history and disease stage where documented
• Additional myeloma-specific metadata available on request

Applications

• FISH cytogenetics and risk-stratification studies
• Marrow microenvironment and bone disease mechanism research
• BCMA-targeted CAR-T and bispecific antibody target-expression studies
• Minimal residual disease assay development
• Plasma cell biology and clonal evolution research

Other Specimen Types

For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Multiple myeloma bone marrow mononuclear cells are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.